Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.79
-0.0500-0.64%
Post-market: 7.78-0.0103-0.13%19:59 EDT
Volume:7.62M
Turnover:59.32M
Market Cap:8.26B
PE:-7.88
High:7.95
Open:7.85
Low:7.60
Close:7.84
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.99
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-7.89
PE(LYR):-20.39

Loading ...

ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed

Simply Wall St.
·
Mar 21

BRIEF-Immunitybio Announces Approval In Macau SAR, China For Anktiva

Reuters
·
Mar 21

ImmunityBio announces approval in Macau for Anktiva

TIPRANKS
·
Mar 21

Macau SAR Regulator Approves ImmunityBio ANKTIVA for BCG-Unresponsive NMIBC CIS

Reuters
·
Mar 21

Immunitybio Announces Approval in Macau SAR, China for Anktiva® in Bcg-Unresponsive Nmibc With CIS ± Papillary Tumors

THOMSON REUTERS
·
Mar 21

Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress

Simply Wall St.
·
Mar 19

Mixed options sentiment in ImmunityBio with shares up 3.53%

TIPRANKS
·
Mar 18

The Stubborn Billionaire Behind the L.A. Times's Revamp -- WSJ

Dow Jones
·
Mar 18

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 17

ImmunityBio announces NCCN Guidelines for Bladder Cancer to include Anktiva

TIPRANKS
·
Mar 17

ImmunityBio cites QUILT-3.032 data as NCCN adds ANKTIVA plus BCG for BCG-unresponsive papillary-only NMIBC

Reuters
·
Mar 17

Immunitybio Announces Nccn® Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva® Plus Bcg for Patients With Bcg-Unresponsive Nmibc With Papillary-Only Disease

THOMSON REUTERS
·
Mar 17

Mixed options sentiment in ImmunityBio with shares down 2.26%

TIPRANKS
·
Mar 17

Update: ImmunityBio Shares Rise After Completion of Scalable M-ceNK Manufacturing Pathway

MT Newswires Live
·
Mar 14

Why Is ImmunityBio Stock Soaring On Friday?

Benzinga_recent_news
·
Mar 13

ImmunityBio reports scalable cryopreserved NK cell production reaching 5 billion cells per apheresis

Reuters
·
Mar 13

ImmunityBio completes Phase 1 QUILT-3.076 trial of M-ceNK plus ANKTIVA in 10 patients

Reuters
·
Mar 13

ImmunityBio Coverage Assumed by BTIG at Buy

Dow Jones
·
Mar 12

U.S. RESEARCH ROUNDUP-AeroVironment, Bumble, Lumentum.

Reuters
·
Mar 12

ImmunityBio assumed with a Buy at BTIG

TIPRANKS
·
Mar 12